MGX vs XLI
Metagenomi, Inc. Common Stock (MGX) versus XLI (XLI) — a side-by-side from cached financials, not a winner call.
Metagenomi, Inc. Common Stock (MGX) is a biotechnology company listed on NASDAQ.
XLI (XLI) common stock.
Latest reported MGX revenue for 2025-12-31 was $25.2M. Net income was -$87.9M. Revenue was down 51.8% from 2024-12-31 to 2025-12-31. MGX currently screens at market cap $44.4M.
XLI does not have a complete income-statement cache yet.
MGX currently screens at market cap $44.4M. XLI currently screens at market cap $0.
Not investment advice. Open the MGX and XLI stock pages for the full models.
Not investment advice.